Bipolar Disorder Medications Compared: Lithium, Lamotrigine, Valproate and Antipsychotics

No single bipolar medication covers every phase of the illness equally well. Lithium is FDA-approved for acute mania and for maintenance in bipolar I disorder; lamotrigine is approved only for maintenance; valproate (divalproex) is approved for manic episodes; and several second-generation antipsychotics are approved for mania, for bipolar depression, or for both. The 2018 CANMAT and ISBD guidelines list lithium, quetiapine, divalproex, lamotrigine, asenapine and aripiprazole among the first-line choices for people starting or switching maintenance treatment.

The right choice depends on which phase is the bigger problem for you (highs, lows or preventing relapse), your other health conditions, whether pregnancy is possible, and how you weigh monitoring against side effects. Every decision to start, combine, change or stop one of these medicines belongs with your prescriber.

Bipolar medications side by side

Lithium: the long-standing standard

Lithium is approved as monotherapy for bipolar I disorder, both for acute manic and mixed episodes and for maintenance, in patients 7 years and older. CANMAT and ISBD list it as first-line for acute mania, bipolar I depression and maintenance.

Its drawback is a narrow margin between a helpful and a harmful level. The label gives a usual target range of 0.8 to 1.2 mEq/L during acute treatment and 0.8 to 1.0 mEq/L for maintenance, while toxic concentrations start at 1.5 mEq/L; your prescriber sets your own target. Before starting, the label calls for checks of kidney function, vital signs, electrolytes, thyroid function, other medicines and pregnancy status. During treatment it advises monitoring kidney and thyroid function and serum calcium. Diuretics, NSAIDs such as ibuprofen, certain blood pressure medicines and metronidazole can raise lithium levels. Dehydration from heavy sweating, diarrhea or fever also raises the risk of toxicity.

For what the blood tests involve and how often they happen, see lithium monitoring: what to expect. If you are choosing between the two most common long-term options, lithium vs lamotrigine goes deeper.

Lamotrigine: prevention, mainly of depression

Lamotrigine's bipolar approval is for maintenance treatment of bipolar I disorder, to delay mood episodes in people already treated for an acute episode. The label states that it is not recommended for acute manic or mixed episodes and that its effectiveness for acute mood episodes has not been established. CANMAT and ISBD list it as first-line for bipolar I depression and maintenance, though not for mania.

Its main risk is a serious rash. In adults, the label estimates serious rash at 0.08% to 0.3%, higher in children, and notes that nearly all life-threatening rashes occurred within 2 to 8 weeks of starting. The risk rises when lamotrigine is combined with valproate, when the starting dose or the dose increases exceed the recommended schedule, or when a person carries the HLA-B*1502 gene variant. That is why lamotrigine starts low and rises slowly, and why restarting after missed days should go through your prescriber.

Valproate and carbamazepine: anticonvulsants for mania

Divalproex is approved for manic episodes in bipolar disorder. The label notes that its effectiveness for long-term use beyond 3 weeks has not been shown in controlled trials, so prescribers who use it longer should keep reassessing its usefulness. CANMAT and ISBD nonetheless list divalproex as first-line for acute mania and maintenance.

Valproate carries one of the most serious boxed warnings in psychiatry. It can cause fatal liver failure, usually in the first six months, so liver tests are needed before starting and often afterward. It can cause major birth defects, particularly neural tube defects such as spina bifida, and lower IQ scores after exposure in pregnancy. The label says valproate should not be used in women of childbearing potential unless other medicines have failed or are otherwise unacceptable, and then with effective contraception. It also warns of pancreatitis.

Extended-release carbamazepine (Equetro) is approved for acute manic or mixed episodes in bipolar I disorder. Its boxed warning covers severe skin reactions, which are strongly linked to the HLA-B*1502 gene variant (testing is advised for people with a higher likelihood of carrying it), and rare but serious drops in blood cells. It can make hormonal contraceptives less effective, and it should not be stopped abruptly.

Second-generation antipsychotics

These medicines differ more than their shared class name suggests. Some are approved mainly for mania, some for bipolar depression, and a few for both:

• For mania or mixed episodes: quetiapine, cariprazine, olanzapine, aripiprazole, risperidone, ziprasidone and asenapine. Milsaperidone (Bysanti), approved in 2026, is also indicated for acute manic or mixed episodes in adults with bipolar I disorder.
• For bipolar depression: quetiapine, lurasidone, cariprazine, lumateperone and the olanzapine-fluoxetine combination. The separate guide to bipolar depression treatment compares these.
• For maintenance: quetiapine (with lithium or divalproex), olanzapine, ziprasidone (with lithium or valproate) and asenapine.

All of them carry a boxed warning that older adults with dementia-related psychosis have a higher risk of death on antipsychotics. Those also approved for depression carry the antidepressant boxed warning about suicidal thoughts in children, adolescents and young adults. The class is associated with weight gain, raised blood sugar and abnormal lipids, though each drug has its own risk profile, and with tardive dyskinesia, a movement disorder. Olanzapine's label notes that its greater potential for weight gain and lipid changes in adolescents may lead clinicians to try other drugs first in that age group. Ziprasidone's label highlights its greater capacity to prolong the QT interval of the heart rhythm compared with several other antipsychotics. The guide to antipsychotic metabolic monitoring covers the checks.

Which medicine for which phase

Two points sit behind this table. First, medicines that work in the acute phase are generally continued into maintenance, with antidepressants as a notable exception. Second, guideline rankings are not the same as FDA labels: some first-line choices, such as lithium for acute bipolar depression, go beyond the labeled indication, which makes them off-label uses. Ask your prescriber how a guideline recommendation applies in your case.

Combinations, injections and other practical choices

Combination treatment

Many people with bipolar I disorder take two medicines, often a mood stabilizer plus an antipsychotic. Several labels are written for exactly that: quetiapine for maintenance alongside lithium or divalproex, ziprasidone for maintenance alongside lithium or valproate, risperidone and asenapine as add-ons to lithium or valproate for mania, and lurasidone and lumateperone as add-ons for bipolar depression. CANMAT and ISBD also list combinations among first-line options for mania and maintenance. Combining adds benefit for some people but also adds side effects and interactions, so the reason for each medicine should be clear.

Long-acting injections

For people who find daily pills hard to keep up with, or who have relapsed after stopping medication, long-acting injectable antipsychotics are an option. Aripiprazole long-acting injection (Abilify Maintena) is approved for maintenance monotherapy of bipolar I disorder in adults. Long-acting risperidone (Risperdal Consta) is approved for maintenance of bipolar I disorder, alone or with lithium or valproate. Injections remove the daily decision to take a pill but are given in a clinic on a set schedule.

Children and teenagers

Fewer options carry pediatric approvals. Lithium is approved from age 7; quetiapine, aripiprazole, risperidone, asenapine and cariprazine have mania indications that extend to age 10 or older; and lurasidone is approved for bipolar I depression from age 10. Olanzapine and quetiapine labels both stress careful diagnosis and weighing risks before treating young people, and olanzapine's flags the higher metabolic risk in adolescents. A child and adolescent psychiatrist is usually the right prescriber for this age group; see choosing a child and adolescent psychiatrist.

Side-effect trade-offs at a glance

Pregnancy, contraception and family planning

Medication choice in bipolar disorder often hinges on whether pregnancy is possible. Valproate has the clearest restriction, described above. Carbamazepine also carries a risk of major birth defects, and it can reduce the effectiveness of hormonal contraception. Early reports linked first-trimester lithium to heart malformations, especially Ebstein's anomaly; the lithium label says later studies suggest this added risk is likely small, though data are insufficient to establish it, and it flags concerns about toxicity for mother and newborn late in pregnancy and after delivery. Planning ahead with your prescriber, ideally before conception, keeps the most options open. See psychiatric medications during pregnancy for the wider picture.

What the evidence does not show

• It does not identify one medicine that is best for everyone; guidelines rank several as first-line for each phase.
• Short acute trials do not always tell you how a medicine performs over years. Divalproex's own label, for example, notes that controlled data beyond 3 weeks of mania treatment are lacking.
• Most trials studied bipolar I disorder. Fewer medicines carry an approval that covers bipolar II; among those in this article, quetiapine and lumateperone are approved for bipolar II depression.
• Supplements and diet changes have not replaced mood stabilizers in controlled trials, and none is FDA-approved for bipolar disorder.

Common mistakes and safety points

• Stopping a mood stabilizer on your own after feeling well for months. Relapse risk is a reason to discuss any change with your prescriber first.
• Taking ibuprofen, naproxen or a new diuretic while on lithium without telling the prescriber who monitors your levels.
• Restarting lamotrigine at your old dose after a break, rather than asking your prescriber how to resume.
• Assuming antidepressant monotherapy is a safe default for bipolar depression; guidance treats antidepressants differently in bipolar I disorder.
• Missing baseline labs before starting, which makes later changes harder to interpret.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Questions to ask your prescriber

• Which phase is this medicine meant to treat or prevent for me, and is that an FDA-approved use or off-label?
• What blood tests do I need before starting and during the first months?
• What side effects should make me call you right away?
• How does this medicine interact with my other prescriptions, contraception or over-the-counter pain relievers?
• If I want to become pregnant in the next few years, would you choose differently?
• How will we judge whether it is working, and what would we try next?

For an overview of what ongoing visits look like, see psychiatric medication management.

How this practice approaches bipolar medication care

Ongoing care at the practice includes psychiatric evaluation and medication management, psychotherapy including CBT and DBT, and lab testing. The team includes psychiatrists and psychiatric nurse practitioners alongside psychotherapists. You can read the practice's page on bipolar disorder treatment and its medication management service, and begin with the Patient Interest Form. More decision guides are collected in Choosing Psychiatric Care.

Frequently asked questions

What is the most effective medication for bipolar disorder?

There is no single best choice. Lithium has the broadest support across mania, depression and maintenance in the 2018 CANMAT and ISBD guidelines, but quetiapine, lamotrigine, divalproex and several antipsychotics are also first-line depending on the phase and your health.

Does lamotrigine treat mania?

No. Lamotrigine is FDA-approved only for maintenance treatment of bipolar I disorder, and its label says it is not recommended for acute manic or mixed episodes.

Why does valproate need special care in women?

Valproate can cause major birth defects and lower IQ after exposure in pregnancy. Its label says it should not be used in women of childbearing potential unless other medicines have failed or are unacceptable, and then with effective contraception.

How often are lithium levels checked?

Your prescriber sets the schedule. The lithium label advises frequent level checks when medicines that raise lithium, such as diuretics or NSAIDs, are added, and notes that fever, sweating and diarrhea increase the risk of toxicity.

Do antipsychotics for bipolar disorder mean I have psychosis?

No. Several second-generation antipsychotics are FDA-approved specifically for mania, bipolar depression or maintenance, whether or not psychosis is present.

Is there anything new for bipolar disorder in 2026?

Milsaperidone (Bysanti) is approved for acute manic or mixed episodes of bipolar I disorder in adults. It is not approved for bipolar depression.

Sources

1. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders (PubMed 29536616), 2018. pubmed.ncbi.nlm.nih.gov
2. Lithium carbonate tablets and capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
3. LAMICTAL (lamotrigine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
4. DEPAKOTE (divalproex sodium) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
5. EQUETRO (carbamazepine) extended-release capsules prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
6. SEROQUEL (quetiapine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
7. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry (PubMed 24030475), 2013. pubmed.ncbi.nlm.nih.gov
8. LATUDA (lurasidone) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
9. VRAYLAR (cariprazine) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
10. CAPLYTA (lumateperone) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
11. Olanzapine and fluoxetine capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
12. ZYPREXA (olanzapine) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
13. ABILIFY (aripiprazole) tablets prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
14. RISPERDAL (risperidone) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
15. GEODON (ziprasidone) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
16. SAPHRIS (asenapine) sublingual tablets prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
17. BYSANTI (milsaperidone) tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
18. ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
19. RISPERDAL CONSTA (risperidone) long-acting injection prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.